It is safe to continue Lexapro 20 mg while planning pregnancy
A healthy woman on escitalopram (Lexapro) 20 mg for anxiety can safely continue this medication while planning conception, as the benefits of maintaining mental health stability typically outweigh the small potential risks to the developing fetus.
Evidence-Based Rationale
The FDA drug label for Lexapro acknowledges that use during pregnancy may lead to neonatal complications but emphasizes the importance of discussing risks versus benefits with healthcare providers 1. The key consideration is that untreated anxiety or depression during pregnancy poses its own substantial risks to both mother and fetus, including preterm birth and decreased maternal functioning 2, 3.
Safety Profile During Pregnancy
Major malformations: Multiple studies demonstrate that escitalopram does not increase the risk of major congenital malformations above baseline population rates 4, 5, 6. The rate of major malformations in exposed pregnancies (approximately 1.7%) falls within the expected range for unexposed women 5.
Perinatal complications: Escitalopram exposure, like other SSRIs, is associated with some perinatal complications 7, 6:
- Transient neonatal adaptation syndrome (irritability, jitteriness, feeding difficulties, respiratory distress) occurring in the first 1-2 weeks after birth
- Slightly increased risk of low birth weight
- Possible persistent pulmonary hypertension of the newborn (PPHN), though evidence remains conflicting 2
These complications are generally mild and self-limited, resolving within 1-4 weeks 7.
Clinical Decision-Making Algorithm
Step 1: Assess severity and treatment history
- Has this patient previously relapsed when discontinuing escitalopram?
- Is her anxiety moderate-to-severe and significantly impacting daily functioning?
- Has she tried and failed non-pharmacologic interventions?
If YES to any of these → Continue escitalopram 8, 3
Step 2: Optimize dosing
- 20 mg is within the therapeutic range
- Consider whether the lowest effective dose has been established
- No need to switch medications if well-controlled on current regimen
Step 3: Preconception counseling
- Discuss the small risks of neonatal adaptation syndrome
- Explain that abrupt discontinuation carries risks of maternal relapse
- Document shared decision-making 3
Step 4: Monitoring plan
- Continue current dose through conception and pregnancy
- Monitor for adequate symptom control
- Prepare pediatric team for possible transient neonatal symptoms at delivery
Why NOT to Switch Medications
Switching to a different anxiolytic is not recommended for several reasons:
No safer alternative exists: All SSRIs carry similar perinatal risk profiles 2, 6. Switching would expose the fetus to a different medication without clear benefit.
Risk of destabilization: Changing medications during the preconception period risks maternal psychiatric decompensation, which itself poses fetal risks 8, 3.
Escitalopram has favorable data: Among SSRIs, escitalopram is well-studied with reassuring safety data regarding major malformations 4, 5, 6.
Benzodiazepines are worse: If considering switching to benzodiazepines for anxiety, these carry their own risks and are generally not preferred for chronic use during pregnancy.
Critical Caveats
Third-trimester exposure carries the highest risk for neonatal adaptation syndrome 7, 1. However, discontinuing late in pregnancy to avoid this often leads to maternal relapse, which is more harmful overall.
Paroxetine and sertraline are often cited as preferred SSRIs during breastfeeding 2, but this should not drive preconception medication changes.
The 2015 American Family Physician guideline notes that antidepressant use during pregnancy has not been shown to improve outcomes like preterm delivery compared to untreated depression 2, but this reflects the severity of untreated illness rather than medication harm.
Document the discussion and enroll in the National Pregnancy Registry for Antidepressants (1-844-405-6185) if pregnancy occurs 1.
Breastfeeding Considerations
Escitalopram passes into breast milk in low concentrations 1, 4. Monitor the infant for excess sedation, poor feeding, or poor weight gain, but continuation during breastfeeding is generally considered acceptable 4, 6.